— -- As Ebola ravages West Africa with more than 700 dead and more than 1,300 infected, officials are desperate for a way to stop the spread of the disease. One possible way to curb the infections is the use of a vaccine that would inoculate those at risk.
In September an Ebola vaccine developed by the U.S. National Institute for Health will be tested in humans for the first time in its first phase 1 clinical trial. If approved, it could be ready for use by mid to late 2015.
But even if deemed safe, the vaccine may not be a silver bullet to ending Ebola.
To test if the vaccine works, scientists will not expose the subjects to Ebola. Instead they will examine the subjects' antibodies as they develop to see if their immune system creates defensive antibodies to fight Ebola the same way primate test subjects did. They will also monitor the subjects' health to ensure the vaccine is safe to use.
If that study goes well, a larger study will be ordered. However, even if the larger study goes well, scientists will still be unsure about how effective the vaccine is because they ethically cannot purposefully expose people to the virus. Additionally Ebola is so rare they cannot give the vaccine to a population of people and know that they will at some point be exposed to the disease.
Dr. William Schaffner, an infectious disease expert from Vanderbilt Medical Center, said the vaccine's effectiveness protecting people from the virus won't likely be fully known until it's tested in the field, such as during an outbreak.
"If you can't do the [final] trial then you're always left with a degree of uncertainty," said Schaffner referring to a phase III study, where some participants are given a vaccine, others a placebo and both groups end up exposed to a pathogen. "When you use [the vaccine] for the first time, you'd want to use it in as rigorous a way possible, which would run into hoopla going on in the midst of an outbreak."
Dr. Stephen Morse, professor of epidemiology at the Columbia University Mailman School of Public Health, said that vaccine would be helpful but not a way to end virus entirely.
"It will provide another tool at least," Morse said. "You can try to contain [Ebola] by immunizing contacts and other people. ... That's essentially the strategy, [a vaccine] would make it a lot easier for healthcare workers."
Because the virus spreads through bodily secretions including blood and urine, it is particularly dangerous to those caring for the very sick. In Sierra Leone, the conditions were so dire that, according to the BBC, nurses were reported to have gone on strike after three of their colleagues died during the outbreak.
While a working vaccine would be a major step towards combatting the deadly virus that can have a fatality rate of 50 percent to 90 percent, more work still needs to be done to educate and win over the population.
Dr. Heinz Feldmann, chief of virology at the U.S. National Institute of Allergy and Infectious Diseases, told The Associated Press it could be difficult to explain the vaccine to groups untrusting of health officials.
"We will have to explain why some people are getting the vaccine and others are not," Feldmann said, adding some West African communities are suspicious of Western aid workers and their treatments. "At the moment, it doesn't even look like the local population wants it."
In some areas, locals have started to wrongly blame health workers for bringing Ebola to their villages. As a result, Dr. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, said making sure the vaccine is safe is extremely important.
"That's the case whenever you have terror and fright and death and people being extraordinarily frightened of things they don't understand," Fauci said.
ABC News' Sydney Lupkin contributed to this report.